Causes of depression

Some describe it as a pervasive grayness that seeps into everything—your morning coffee, conversations with loved ones, and the activities that once sparked joy. Others speak of an invisible weight, a heavy burden that makes the simple act of getting out of bed feel like a task for the entire day. Still others find it impossible to name at all—they just feel that something is fundamentally “off,” that they aren’t their usual selves, and they don’t understand why.

Depression has many faces. And—just as importantly—it has many causes.

There is no single gene, no single traumatic childhood, and no single stressor that triggers it. For one person, biology may play the leading role: a vulnerability hardwired into the nervous system, hormonal imbalances, or chronic inflammation. For another, it might be years of unmet emotional needs, the loss of a loved one, or the crushing sense that there is no place for them in this world. More often than not, it is a complex tangle of all these factors, compounded by sleep deprivation, loneliness, overwork, and a body that has finally reached its breaking point.

This is why there is no single treatment for depression—just as there is no single “type” of depression.

This article was written to help you understand what truly lies beneath this diagnosis. Whether you are personally struggling with depression, trying to better understand a loved one, or are a psychiatrist or psychologist looking for a reliable, up-to-date review of the current literature—you will find an exploration of all the key drivers here: from brain neurobiology and trauma to cognitive patterns, hormones, diet, genetics, and the social environment.

Because understanding the causes is the first step toward changing the outcome.

The Biopsychosocial Model – Why Depression Has No Single Cause

Depression rarely results from a single, isolated factor. Population and clinical studies consistently indicate that it is the outcome of overlapping risk and protective factors, acting in parallel and in varying proportions for different individuals [1]. The biopsychosocial model, first proposed by George Engel in 1977 and refined over the following decades, currently serves as the fundamental paradigm for understanding depression in both psychiatry and clinical psychology.

Within this model, we distinguish between three interconnected levels:

Biological level: Genetics, neurochemistry, hormones, inflammatory processes, and somatic (physical) illnesses.
Psychological level: Thought patterns, emotional regulation, trauma history, and attachment styles.
Social level: Relational support, economic stressors, cultural norms regarding emotions, and loneliness.

It is crucial to differentiate between predisposing factors (which increase general vulnerability), precipitating factors (the “triggers” leading to a specific episode), and perpetuating factors (those that prevent recovery). The same event—for instance, losing a job—might act as a trigger for an individual with a strong biological predisposition, while being merely a temporary stressor for someone with robust psychological resources and a strong social support system.

Understanding the multi-faceted nature of depression has direct clinical implications: effective treatment often requires a multi-pronged approach, encompassing pharmacotherapy, psychotherapy, and the modification of environmental factors [1].

Neurobiological Causes of Depression: Neurotransmitters, Mood Circuits, and Neuroplasticity

Serotonin, Norepinephrine, and Dopamine

Pop-science depictions of depression often reduce the condition to a simple “serotonin deficiency.” However, modern neurobiology offers a much more nuanced picture. While serotonin, norepinephrine, and dopamine are indeed involved in regulating mood, motivation, sleep, and the brain’s reward system, their role is not a matter of a simple “lack” of a single substance [1].

The monoamine hypothesis of depression, while a vital starting point for pharmacotherapy (as medications like SSRIs, SNRIs, and TCAs target these systems), has its limitations. For instance, antidepressants increase neurotransmitter levels within hours, yet the clinical effect typically takes 2–6 weeks to manifest. This suggests that the mechanism of action is far more complex, likely involving adaptive changes in receptor expression, neuroplasticity, and neuroprotective processes.

Neuroplasticity and BDNF

One of the most promising areas of research is the role of BDNF (Brain-Derived Neurotrophic Factor) in the pathophysiology of depression. Meta-analyses indicate lower serum concentrations of BDNF in patients with depression compared to healthy control groups. Furthermore, effective treatment—both pharmacological and psychotherapeutic—is associated with an increase in BDNF levels [2].

BDNF supports the survival, growth, and plasticity of neurons, particularly in the hippocampus—a brain region critical for memory, learning, and emotional regulation. Chronic stress has been shown to reduce hippocampal volume in both humans and animals, which may explain the memory and concentration issues frequently observed in depression. This neuroplastic perspective on depression is consistent with the fact that both medication and physical exercise increase BDNF expression.

Mood Circuits – The Role of the Amygdala and the Prefrontal Cortex

Depression is linked to dysfunction within the neural networks involving the amygdala, the prefrontal cortex (PFC), and the hippocampus. Neuroimaging studies (fMRI) demonstrate a hyper-reactivity of the amygdala to negative stimuli, alongside weakened top-down control by the prefrontal cortex over emotional responses in individuals with depression.

Furthermore, the Default Mode Network (DMN)—which is typically active during rumination and self-referential thought—shows heightened activity during depressive episodes. This may explain the persistent tendency toward intrusive, negative thought patterns often seen in patients.

The HPA Axis, Cortisol, and Stress Regulation

The hypothalamic-pituitary-adrenal (HPA) axis serves as the body’s central stress response system. When a threat is perceived, it secretes cortisol, which mobilizes energy, suppresses the immune system, and prepares the body for a “fight or flight” reaction. While this response is adaptive in the short term, chronic activation leads to systemic issues.

Numerous studies have observed signs of HPA axis hyperactivity in a subset of patients with depression [3]. A meta-analysis by Zajkowska et al. (2022), which examined longitudinal studies among adolescents and young adults, suggests that elevated cortisol may be a risk factor for subsequent depressive episodes, though the effect is moderate and highly dependent on the timing of the measurement [11].

However, it is important to note that the clinical picture is not uniform. In some patients—particularly those with atypical depression or a long-term course of illness—researchers observe a blunted or hyporeactive cortisol response. This suggests a secondary desensitization of glucocorticoid receptors. This distinction is clinically vital: there is no single “cortisol profile” for depression; it varies significantly depending on the subtype and stage of the disorder.

The mechanisms through which chronic stress can lead to depression include: – The neurotoxic effects of cortisol on the hippocampus.
– The inhibition of neuroplasticity (lowering BDNF levels).
– Sleep disturbances.
– Increased systemic inflammation.
– Disruption of neurotransmitter regulation.

Inflammation as a Biological Risk Factor for Depression

Over the past two decades, there has been growing interest in the role of inflammatory processes in the pathophysiology of depression. Meta-analyses indicate that a subset of patients with depression exhibits elevated inflammatory markers—pro-inflammatory cytokines, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and C-reactive protein (CRP) [12].

Elgellaie et al. (2023), in a systematic review, confirm a significant link between elevated concentrations of IL-1alpha, IL-6, and TNF-alpha and major depressive disorder [12]. These cytokines can influence mood through several key mechanisms:

Inhibition of serotonin synthesis: This occurs through the activation of the IDO enzyme (indoleamine-2,3-dioxygenase), which shunts tryptophan—the precursor to serotonin—away from serotonin production and toward the kynurenine pathway.
Direct action on the central nervous system: Cytokines can cross the blood-brain barrier or stimulate the vagus nerve, sending inflammatory signals directly to the brain.
Disruption of neuroplasticity: Inflammation can negatively impact the expression of BDNF, hindering the brain’s ability to repair and adapt.
HPA axis dysregulation: Cytokines can interfere with the feedback loops of the stress response system and cortisol secretion.

Elevated inflammation is particularly common in patients with depression who also struggle with comorbid obesity, diabetes, cardiovascular disease, or those recovering from severe infections. It is clinically significant that this subgroup of patients may respond less effectively to traditional antidepressants. Pilot studies suggest that anti-inflammatory medications may hold therapeutic potential for depression characterized by high inflammation—though this remains a field requiring further large-scale randomized controlled trials.

However, caution is warranted in interpretation: inflammation is neither the sole cause nor a specific marker for depression. Its role represents one of many biological pathways and pertains to a specific subgroup of patients.

Psychological Causes of Depression: Cognitive Schemas, Self-Esteem, and Rumination

Beck’s Cognitive Triad

The cognitive model of depression, developed by Aaron T. Beck in the 1960s and 70s, remains one of the most empirically well-researched psychological frameworks. At its core is the so-called cognitive triad: negative beliefs about the self (“I am worthless”), the world (“Everything is meaningless; others are hostile”), and the future (“Nothing will ever change”) [7].

Golonka et al. (2024), in an article published in Psychiatria Polska, describe current developments in cognitive theory, highlighting the role of cognitive schemas as stable belief structures that become particularly active in the face of stress [7]. These schemas are not merely “negative thoughts”; they are deep-seated convictions about oneself and the world, shaped by years of experience, that dictate how new events are interpreted.

Rumination

Rumination—the intrusive, circular habit of overthinking problems and negative emotional states—is one of the strongest psychological predictors of depressive episodes and relapses. Unlike constructive problem-solving, rumination is characterized by passivity, a focus on the causes and consequences of distress rather than solutions, and a tendency toward over-generalization.

Meta-analyses consistently show that high levels of rumination prospectively predict an increase in depressive symptoms, even when controlling for baseline levels of depression and other variables. Furthermore, rumination is the primary mechanism through which stressful life events translate into depressive symptoms: it is not the loss itself, but the way one thinks about it, that determines the risk of clinical depression.

Low Self-Esteem and Self-Criticism

Low self-esteem serves as both a risk factor and a symptom of depression, creating a vicious cycle that is difficult to break without therapeutic intervention. Particularly pathogenic is self-criticism—the tendency to judge oneself harshly for failures and perceived imperfections.

Research by Paul Gilbert and others within the framework of Compassion-Focused Therapy (CFT) indicates that high self-criticism is linked to the activation of the brain’s “threat system” (the stress response) without the concurrent activation of the “soothing system.” This imbalance effectively traps the individual in, and sustains, a depressive state.

Learned Helplessness and the Perceived Lack of Control

Seligman’s classic theory of learned helplessness (1975), which was later expanded by Abramson, Seligman, and Teasdale into attributional theory, suggests that the experience of uncontrollable negative events leads to a deep-seated belief in one’s own helplessness. This belief then generalizes to new, even controllable situations.

When an individual’s attributional style is internal (“it’s my fault”), stable (“it will always be this way”), and global (“everything I do fails”), the risk of clinical depression increases significantly. Essentially, if you stop believing that your actions can change your outcome, your brain eventually stops trying, leading to the profound lethargy and despair characteristic of the disorder.

Trauma and Early Childhood Experiences as Causes of Depression

Adverse Childhood Experiences (ACEs)—which include physical, emotional, and sexual abuse, neglect, domestic violence, parental substance abuse, or parental mental illness—are among the strongest predictors of mental health disorders in adulthood, including depression.

A monumental study by Hughes et al. (2017), published in The Lancet Public Health, involved a meta-analysis of 37 studies with over 250,000 participants. It revealed that individuals with four or more ACEs have nearly three times the risk of developing depression and anxiety in adulthood compared to those with no such experiences [6]. This effect is robust and remains significant regardless of various socio-demographic factors.

The mechanisms through which early trauma increases vulnerability to depression include:

Permanent changes in HPA axis regulation: Children raised in chronic stress may develop a permanently altered stress-reactivity threshold.
Disruption of neuroplasticity: Chronic early-life stress can inhibit the development of the hippocampus and the prefrontal cortex.
Formation of insecure attachment styles: These translate into difficulties with emotional regulation and a heightened sensitivity to rejection in adulthood [9].
Entrenched cognitive schemas: Early experiences shape core beliefs about oneself, others, and the world, predisposing the individual to depressive interpretations of life events.
Epigenetic modifications of gene expression: Research indicates long-term changes in DNA methylation that regulate glucocorticoid receptor genes in individuals who have experienced childhood trauma.

Yrondi et al. (2022) demonstrated in a meta-analysis that a history of childhood trauma is associated with a poorer response to depression treatment—both pharmacological and psychotherapeutic [10]. This clinical significance of trauma history underscores the vital need for routine developmental histories in psychiatry and clinical psychology.

An important caveat: Trauma is not destiny. Many individuals who experience difficult childhoods do not develop depression, especially if they have access to supportive relationships, psychological resources, or receive early therapeutic intervention. Resilience is an empirically documented phenomenon and serves as a crucial focal point for prevention and recovery.

Life Stress, Critical Events, and Environmental Factors

Stressful life events are among the most extensively researched and clinically validated triggers for depressive episodes. Bjorndal et al. (2023), in a large-scale population study of Norwegian twins, demonstrated that stressful life events significantly increase the risk of a major depressive episode, an association that persists even after controlling for shared genetic and environmental backgrounds [5].

The most potent stressors include:

Bereavement and the loss of a loved one.
Relationship breakdown or divorce.
Job loss or severe financial difficulties.
Serious illness, whether personal or involving a loved one.
Physical, sexual, or psychological violence.
Social conflict and isolation.
Chronic workplace issues (burnout, mobbing).

Crucially, it is not just the intensity of the stressor but its chronicity and the perceived inability to escape the situation. The concept of “uncontrollable stress” is vital: situations where an individual feels they have no agency over their stressors are particularly destructive to mental health. This explains why poverty, discrimination, and domestic violence—as chronic, difficult-to-control stressors—are so strongly linked to higher depression prevalence.

Environmental risk factors also include: noise pollution, air pollution (with increasing data linking PM_{2.5} exposure to depression risk), a lack of green spaces, shift work that disrupts circadian rhythms, excessive social media use (particularly in adolescents), and exposure to violence in the media.

The quality and availability of social support is one of the strongest predictors of mental health—acting both as a protective factor and, in its absence, a significant risk factor for depression. Li et al. (2023), in a meta-analysis of dozens of studies, confirmed the protective effect of social support, identifying several key mechanisms: instrumental support (practical help), informational support, emotional support, and a sense of belonging [8].

It is worth noting that perceived support (the subjective feeling that one is surrounded by caring people) carries more weight than the objective number of social contacts. One can have many acquaintances yet feel profoundly lonely—and vice versa.

The COVID-19 pandemic served as a natural experiment on the effects of social isolation. Meta-analyses showed a significant global increase in the prevalence of depression and anxiety during 2020–2021, particularly among those who experienced prolonged isolation and a loss of social ties.

Depression and isolation often create a vicious cycle: depressive symptoms (withdrawal, anhedonia, feeling like a “burden”) lead to reduced social contact, which in turn deepens the depression. Recognizing and breaking this cycle is a cornerstone of effective treatment plans.

Genetic Factors in Depression

Depression exhibits moderate heritability. A classic meta-analysis by Sullivan et al. (2000) involving twin studies estimated the heritability of major depression at approximately 37% [14]. This means that genetics account for less than half of the variance in risk; the remainder is explained by environmental factors and individual experiences.

Flint (2023), in a review published in Molecular Psychiatry, summarizes the current state of knowledge: genome-wide association studies (GWAS) have identified dozens of genetic loci associated with depression risk, but each explains only a tiny fraction of the variance [15]. This confirms that depression is a polygenic disorder—genetic risk is “distributed” across hundreds of genetic variants rather than concentrated in a few key genes.

The research on the MKP-1 (DUSP1) gene from Yale, conducted by Duric et al. (2010), found increased expression of this negative regulator of MAP kinases in the brain tissue of depressed individuals. Manipulating this gene in animal models resulted in depressive-like behaviors [16]. This is a major neurobiological discovery regarding neuronal plasticity, though—like all molecular research—it does not yet translate directly into individual diagnostics.

The controversial, though widely cited, hypothesis regarding the interaction between the serotonin transporter gene (5-HTTLPR) and stress was challenged by a large meta-analysis by Risch et al. (2009), which failed to confirm the expected modulatory effect [17]. This serves as an important lesson on the limitations of oversimplifying genetic research for a general audience.

Practical takeaway for patients and clinicians: A family history of depression increases risk but does not guarantee the illness. Conversely, a lack of family history does not protect an individual if strong environmental factors are present. Currently, genetic tests for depression risk lack clinical utility for individual patients.

Hormones and Depression: Thyroid, Reproductive Cycle, Menopause, and Postpartum Depression

Thyroid Disorders

The link between hypothyroidism and depression is one of the best-documented connections in biological psychiatry. Bode et al. (2021), in a meta-analysis published in JAMA Psychiatry, demonstrated significant comorbidity between hypothyroidism and depression [2]. Symptoms of an underactive thyroid—such as psychomotor retardation, fatigue, impaired concentration, low mood, and weight gain—can perfectly mimic or exacerbate clinical depression.

It is a clinical standard that any patient presenting with depressive symptoms should have their thyroid function screened, typically by measuring TSH, free T4, and free T3 levels. Conversely, hyperthyroidism (an overactive thyroid) can trigger anxiety, irritability, and dysphoric episodes. Additionally, autoimmune thyroiditis (Hashimoto’s disease) is associated with a specific profile of neuropsychiatric symptoms that may persist even when TSH levels are technically within the normal range.

Postpartum and Perinatal Depression

Perinatal depression—which encompasses both the pregnancy and the postpartum period—affects approximately 10–15% of women [4]. The risk stems from a volatile intersection of rapid hormonal shifts (specifically the sharp drop in estrogen and progesterone after birth), sleep deprivation, caregiving burdens, societal pressures, and a history of mood disorders.

According to StatPearls (2025), perinatal depression is formally defined by the “with perinatal onset” specifier in the DSM-5 and ICD-11. It can begin during pregnancy, not just after delivery [4]. This is a vital clinical distinction, as many women remain undiagnosed until after the child is born. Key risk factors include previous depressive episodes, lack of partner support, unplanned pregnancy, traumatic birth, and psychosocial stress.

Menopause and Perimenopause

A study by Badawy et al. (2024) in the Journal of Affective Disorders found that perimenopause—the transitional period preceding the final menstrual period—is associated with a significantly higher risk of depression compared to the premenopausal years [13]. Mechanisms include estrogen fluctuations (which modulate the serotonergic and dopaminergic systems), sleep disturbances linked to hot flashes, and the overlapping life stressors characteristic of middle adulthood.

Premenstrual Dysphoric Disorder (PMDD)

PMDD is a severe, cyclical form of mood disorder linked to the luteal phase of the menstrual cycle. Affecting approximately 3–8% of women of reproductive age, it is characterized by intense depressive symptoms, irritability, and functional impairment in the week before menstruation, with full remission following its onset. It is formally recognized in the DSM-5 as a distinct diagnostic entity and requires specific treatment strategies, such as targeted SSRI use or hormonal interventions.

Sleep, Physical Activity, and Diet as Risk Factors for Depression

Sleep Disorders

Insomnia and depression exist in a bidirectional relationship: insomnia is both a symptom and a major risk factor for the development of depression. Meta-analyses show that individuals with chronic insomnia have twice the risk of developing depression compared to those without sleep issues. Chronic sleep deprivation disrupts emotional regulation, increases amygdala reactivity, lowers prefrontal cortex activity, and fuels systemic inflammation.

Circadian rhythms also play a pivotal role. Chronobiological disruptions (such as shift work or “social jet lag”) are linked to higher depression risk. Research into light therapy for Seasonal Affective Disorder (SAD) and the regulation of circadian rhythms further confirms the biological bridge between the sleep-wake cycle and mood.

Physical Activity

Regular physical exercise is one of the most robustly documented non-pharmacological interventions for both the treatment and prevention of depression. Its mechanisms include: increasing BDNF expression, regulating the HPA axis, reducing inflammatory markers, improving sleep quality, and boosting psychological “self-efficacy.”

Meta-analyses of randomized clinical trials show a moderate to strong effect of physical exercise on depressive symptoms, comparable in some analyses to the effects of pharmacotherapy for mild to moderate depression. Aerobic activities (running, cycling, swimming) have the strongest evidence base, though resistance training and yoga also show significant benefits.

Diet and the Gut Microbiome

The gut-brain axis is a rapidly evolving field of research. The gut microbiome influences serotonin synthesis (over 90% of the body’s serotonin is produced in the gut), produces neuroprotective short-chain fatty acids, and modulates both inflammation and the HPA axis.

Observational meta-analyses indicate that the Mediterranean diet (rich in vegetables, fruits, fish, olive oil, and nuts) is associated with a lower risk of depression, while highly processed diets rich in simple sugars correlate with higher risk. Intervention studies, such as the SMILES trial (2017), suggest that dietary improvement can lead to significant symptom relief—though more large-scale randomized trials are needed.

Micronutrient deficiencies—specifically Omega-3 fatty acids, Vitamin D, magnesium, zinc, and iron—are also studied as potential modifiable risk factors. Meta-analyses on Omega-3 supplementation show a moderate supportive effect, particularly when used alongside traditional pharmacotherapy.

Somatic Illnesses and Chronic Pain

Depression frequently co-occurs with chronic physical conditions, and the relationship is often bidirectional. Read et al. (2017), in a systematic review and meta-analysis, confirmed that multimorbidity significantly increases the risk of depression [18]. Cardiovascular diseases, diabetes, chronic neurological conditions, cancers, and autoimmune diseases—all of these states are associated with a prevalence of depression at least twice as high as that of the general population.

Aaron et al. (2025), in a large-scale study published in JAMA Network Open, demonstrated that the prevalence of depression and anxiety among adults with chronic pain is exceptionally high—chronic pain is one of the strongest predictors of clinically significant depression [19]. The mechanisms involved include shared neurobiological pathways (dysregulation of the opioid, serotonergic, and noradrenergic systems), chronic stress, restricted activity, social isolation, and insomnia.

Clinically significant conditions linked to depression risk include:

Thyroid disorders (particularly hypothyroidism—see section 10).
Diabetes: Meta-analyses indicate a twofold increase in depression risk.
Parkinson’s disease: Up to 40% of patients experience clinically significant depression.
Multiple Sclerosis (MS): Depression prevalence is approximately 50%.
Cardiovascular diseases: Post-myocardial infarction depression is an independent factor for a poorer prognosis.
Cancer: Depression is the most common mental health disorder among oncological patients.
Chronic inflammatory diseases (RA, Crohn’s disease, psoriasis): Likely linked through shared inflammatory pathways.

Substances, Psychoactive Drugs, and Medications

Alcohol is one of the substances most commonly linked to depression. Although many individuals turn to alcohol to alleviate depressive symptoms (“self-medication”), it is a central nervous system depressant. While it may provide short-term relief, long-term use worsens mood dysregulation, disrupts sleep, and deepens depressive symptoms. Alcohol dependence and depression often form a self-perpetuating feedback loop.

A similar dynamic applies to certain narcotics: cocaine, amphetamines, and other stimulants can trigger depressive episodes during the withdrawal phase (“the crash”). Chronic cannabis use, particularly varieties with high THC content, is linked to an increased risk of mood and psychotic disorders, especially in individuals with genetic predispositions or those who began use during adolescence.

Medications that may potentially trigger depressive symptoms include:

Certain antihypertensives (beta-blockers, clonidine).
Corticosteroids (with long-term use).
Benzodiazepines (paradoxically, during withdrawal or chronic use).
Isotretinoin (used for acne—though the link remains controversial).
Hormonal medications and Interferon alpha (used for Hepatitis C and certain cancers—a well-documented depressive effect).

Depression across Gender, Age, and Culture

Gender Differences

Depression is diagnosed twice as often in women as in men in most Western populations. The causes are multifaceted and go beyond biology: women are more likely to seek help and disclose emotional symptoms, whereas men often mask depression with alcohol, aggression, or workaholism (“masked depression”). Paradoxically, men have a higher rate of completed suicides, suggesting that their depression is frequently underdiagnosed and undertreated.

Depression in Different Age Groups

Adolescents: The rise in depression risk during puberty is well-documented, linked to biological maturation, identity shifts, and peer/academic pressure. Social media use and cyberbullying play a specific role here.
Seniors: Depression in the elderly is often underdiagnosed because symptoms may be masked by physical complaints or dismissed as “natural aging.” Risk factors include isolation, bereavement, chronic illness, and loss of independence.

Cultural Factors

Culture influences how depression is experienced, expressed, and discussed. In cultures where the stigma of mental illness is high, individuals often report somatic symptoms (pain, fatigue) instead of emotional ones. Cultural norms regarding emotional expression and gender roles significantly modulate the course and treatment of the disorder.

Summary: An Integrative Model of Depression

The causes of depression form a complex web of interdependencies. No single factor—biological, psychological, or environmental—fully explains why a specific person develops depression at a specific time. The best available framework remains the biopsychosocial model, which integrates:

Biological predispositions: Genetics, neurochemistry, hormones, inflammation, and somatic illness.
Psychological risk factors: Cognitive schemas, rumination, self-criticism, trauma history, and attachment styles.
Environmental and social burdens: Life stress, isolation, poverty, violence, and lack of support.
Modifiable factors: Sleep, physical activity, diet, substance use, and relationships.

For clinicians, this necessitates a multi-dimensional assessment of every patient. For patients and their families, it is vital to understand that depression is not a weakness of character or a choice, but a complex health disorder with many determinants and effective treatment methods.

Bibliography

World Health Organization (WHO). Depressive disorder (depression) – Fact sheet (aktualizacja: 29 Aug 2025). https://www.who.int/news-room/fact-sheets/detail/depression
Bode H. i wsp. Association of Hypothyroidism and Clinical Depression: Systematic Review and Meta-analysis. JAMA Psychiatry (2021). https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2784329
Keller J. i wsp. HPA Axis in Major Depression: Cortisol, Clinical Symptomatology, and Genetic Variation. Front Psychiatry (2017). https://pmc.ncbi.nlm.nih.gov/articles/PMC5313380/
NCBI Bookshelf (StatPearls). Perinatal Depression (aktualizacja: 22 Jan 2025). https://www.ncbi.nlm.nih.gov/books/NBK519070/
Bjorndal L.D. i wsp. Stressful life events increase the risk of major depressive episodes: a population-based twin study. Psychol Med (2023). https://pmc.ncbi.nlm.nih.gov/articles/PMC10476058/
Hughes K. i wsp. The effect of multiple adverse childhood experiences on health: a systematic review and meta-analysis. The Lancet Public Health (2017). https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(17)30118-4/fulltext
Golonka K. i wsp. Study directions and development of cognitive theory of depression. Psychiatria Polska (2024). https://www.psychiatriapolska.pl/pdf-161676-116049
Li G. i wsp. Understanding the protective effect of social support on depression: meta-analytic evidence and mechanisms. (2023). https://pmc.ncbi.nlm.nih.gov/articles/PMC10689368/
Rajkumar R.P. Comorbid depression and anxiety: integration of insights. Front Behav Neurosci (2022). https://www.frontiersin.org/journals/behavioral-neuroscience/articles/10.3389/fnbeh.2022.1104928/full
Yrondi A. i wsp. Treatment efficacy and effectiveness in adults with major depressive disorder and childhood trauma history: a meta-analysis. (2022). https://pubmed.ncbi.nlm.nih.gov/36156242/
Zajkowska Z. i wsp. Cortisol and development of depression in adolescence and young adulthood: systematic review and meta-analysis. (2022). https://www.sciencedirect.com/science/article/pii/S0306453021004996
Elgellaie A. i wsp. Pro-inflammatory cytokines IL-1alpha, IL-6 and TNF-alpha in major depressive disorder. Eur J Neurosci (2023). https://onlinelibrary.wiley.com/doi/10.1111/ejn.15992
Badawy Y. i wsp. The risk of depression in the menopausal stages. J Affect Disord (2024). https://www.sciencedirect.com/science/article/pii/S0165032724006438
Sullivan P.F. i wsp. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry (2000). https://pubmed.ncbi.nlm.nih.gov/11007705/
Flint J. The genetic basis of major depressive disorder. Mol Psychiatry (2023). https://www.nature.com/articles/s41380-023-01957-9
Duric V. i wsp. A negative regulator of MAP kinase causes depressive behavior (MKP-1/DUSP1). Nat Med (2010). https://pmc.ncbi.nlm.nih.gov/articles/PMC3066515/
Risch N. i wsp. Interaction between 5-HTTLPR genotype and stressful life events in depression: meta-analysis. JAMA (2009).
Read J.R. i wsp. Multimorbidity and depression: a systematic review and meta-analysis. J Affect Disord (2017). https://www.sciencedirect.com/science/article/abs/pii/S0165032717303464
Aaron R.V. i wsp. Prevalence of Depression and Anxiety Among Adults With Chronic Pain. JAMA Network Open (2025). https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831134